Adjuvant Systems
Adjuvant systems are critical components of vaccines that enhance immune response and efficacy. We aim to provide reliable supply and open access to advanced adjuvant systems, addressing significant unmet needs in vaccine development and accelerating the availability of these technologies to healthcare providers and patients globally.
SPI Pharma and Inimmune, have created a strategic collaboration to develop and commercialize advanced adjuvant systems for vaccine development. The collaboration leverages Inimmune's world-class expertise in adjuvant formulation and immunotherapeutics and SPI Pharma's extensive manufacturing and global commercial capabilities.
Partnering with Inimmune:
Inimmune is a leader in the discovery and development of vaccine adjuvants with over 20 years of expertise in their safe and effective use. Inimmune’s novel small molecule adjuvants can activate the immune system in specific ways to drive the right immune response to deliver protection against pathogens of interest. Our lead vaccine adjuvants target innate immune receptors TLR4, TLR7/8, and Mincle and are focused on generating Th1 and Th17 responses. We are also working on discovering new adjuvants that target STING as well as inflammasome-activating adjuvants. Additionally, our formulations team has extensive expertise in tailoring vaccine delivery systems for these innate immune agonists, to match the route of administration and dosing required for a given indication.
Dedication to Innovation and New Technology
We are expanding our portfolio to offer advanced vaccine systems and explore additional technologies. Our strategy is to advance new vaccine development with these materials.
RELATED PRODUCTS
Valens™ T4Q is a AS01®-like adjuvant system combining Inimmune’s novel synthetic TLR4 agonist, INI-2002, with saponin adjuvants from SPI Pharma (Download the brochure).
AS01® is a registered trademark of GSK Biologicals S.A.
Valens™ T4AH is a AS04-like adjuvant system combining Inimmune’s novel synthetic TLR4 agonist, INI-2002, with alum adjuvants from SPI Pharma (Download the brochure).
